These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

205 related items for PubMed ID: 23115635

  • 1. Regulation of epidermal growth factor receptor signaling and erlotinib sensitivity in head and neck cancer cells by miR-7.
    Kalinowski FC, Giles KM, Candy PA, Ali A, Ganda C, Epis MR, Webster RJ, Leedman PJ.
    PLoS One; 2012; 7(10):e47067. PubMed ID: 23115635
    [Abstract] [Full Text] [Related]

  • 2. Axl mediates acquired resistance of head and neck cancer cells to the epidermal growth factor receptor inhibitor erlotinib.
    Giles KM, Kalinowski FC, Candy PA, Epis MR, Zhang PM, Redfern AD, Stuart LM, Goodall GJ, Leedman PJ.
    Mol Cancer Ther; 2013 Nov; 12(11):2541-58. PubMed ID: 24026012
    [Abstract] [Full Text] [Related]

  • 3. Regulation of epidermal growth factor receptor signaling in human cancer cells by microRNA-7.
    Webster RJ, Giles KM, Price KJ, Zhang PM, Mattick JS, Leedman PJ.
    J Biol Chem; 2009 Feb 27; 284(9):5731-41. PubMed ID: 19073608
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. [Molecular mechanism of erlotinib resistance in epidermal growth factor receptor mutant non-small cell lung cancer cell line H1650].
    Han R, Wang X, Zhong D, Zhao J, Chen Z, Sun L, Wang J, Zhang J.
    Zhongguo Fei Ai Za Zhi; 2012 Dec 27; 15(12):689-93. PubMed ID: 23249714
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. The TGFβ-miR-499a-SHKBP1 pathway induces resistance to EGFR inhibitors in osteosarcoma cancer stem cell-like cells.
    Wang T, Wang D, Zhang L, Yang P, Wang J, Liu Q, Yan F, Lin F.
    J Exp Clin Cancer Res; 2019 May 28; 38(1):226. PubMed ID: 31138318
    [Abstract] [Full Text] [Related]

  • 8. Inactivation of Akt by the epidermal growth factor receptor inhibitor erlotinib is mediated by HER-3 in pancreatic and colorectal tumor cell lines and contributes to erlotinib sensitivity.
    Buck E, Eyzaguirre A, Haley JD, Gibson NW, Cagnoni P, Iwata KK.
    Mol Cancer Ther; 2006 Aug 28; 5(8):2051-9. PubMed ID: 16928826
    [Abstract] [Full Text] [Related]

  • 9. Cotargeting of epidermal growth factor receptor and PI3K overcomes PI3K-Akt oncogenic dependence in pancreatic ductal adenocarcinoma.
    Wong MH, Xue A, Julovi SM, Pavlakis N, Samra JS, Hugh TJ, Gill AJ, Peters L, Baxter RC, Smith RC.
    Clin Cancer Res; 2014 Aug 01; 20(15):4047-58. PubMed ID: 24895459
    [Abstract] [Full Text] [Related]

  • 10. Kaempferol potentiates the sensitivity of pancreatic cancer cells to erlotinib via inhibition of the PI3K/AKT signaling pathway and epidermal growth factor receptor.
    Zhang Z, Guo Y, Chen M, Chen F, Liu B, Shen C.
    Inflammopharmacology; 2021 Oct 01; 29(5):1587-1601. PubMed ID: 34322786
    [Abstract] [Full Text] [Related]

  • 11. ErbB3 expression and dimerization with EGFR influence pancreatic cancer cell sensitivity to erlotinib.
    Frolov A, Schuller K, Tzeng CW, Cannon EE, Ku BC, Howard JH, Vickers SM, Heslin MJ, Buchsbaum DJ, Arnoletti JP.
    Cancer Biol Ther; 2007 Apr 01; 6(4):548-54. PubMed ID: 17457047
    [Abstract] [Full Text] [Related]

  • 12. Sensitivity of non-small cell lung cancer to erlotinib is regulated by the Notch/miR-223/FBXW7 pathway.
    Zhang H, Chen F, He Y, Yi L, Ge C, Shi X, Tang C, Wang D, Wu Y, Nian W.
    Biosci Rep; 2017 Jun 30; 37(3):. PubMed ID: 28507201
    [Abstract] [Full Text] [Related]

  • 13. Insights into erlotinib action in pancreatic cancer cells using a combined experimental and mathematical approach.
    Lange F, Rateitschak K, Kossow C, Wolkenhauer O, Jaster R.
    World J Gastroenterol; 2012 Nov 21; 18(43):6226-34. PubMed ID: 23180942
    [Abstract] [Full Text] [Related]

  • 14. NOX4 mediates cytoprotective autophagy induced by the EGFR inhibitor erlotinib in head and neck cancer cells.
    Sobhakumari A, Schickling BM, Love-Homan L, Raeburn A, Fletcher EV, Case AJ, Domann FE, Miller FJ, Simons AL.
    Toxicol Appl Pharmacol; 2013 Nov 01; 272(3):736-45. PubMed ID: 23917044
    [Abstract] [Full Text] [Related]

  • 15. Effect of erlotinib on epidermal growth factor receptor and downstream signaling in oral cavity squamous cell carcinoma.
    Tsien CI, Nyati MK, Ahsan A, Ramanand SG, Chepeha DB, Worden FP, Helman JI, D'Silva N, Bradford CR, Wolf GT, Lawrence TS, Eisbruch A.
    Head Neck; 2013 Sep 01; 35(9):1323-30. PubMed ID: 22907806
    [Abstract] [Full Text] [Related]

  • 16. Rapamycin synergizes with the epidermal growth factor receptor inhibitor erlotinib in non-small-cell lung, pancreatic, colon, and breast tumors.
    Buck E, Eyzaguirre A, Brown E, Petti F, McCormack S, Haley JD, Iwata KK, Gibson NW, Griffin G.
    Mol Cancer Ther; 2006 Nov 01; 5(11):2676-84. PubMed ID: 17121914
    [Abstract] [Full Text] [Related]

  • 17. CIP2A mediates erlotinib-induced apoptosis in non-small cell lung cancer cells without EGFR mutation.
    Wang CY, Chao TT, Chang FY, Chen YL, Tsai YT, Lin HI, Huang YC, Shiau CW, Yu CJ, Chen KF.
    Lung Cancer; 2014 Aug 01; 85(2):152-60. PubMed ID: 24954871
    [Abstract] [Full Text] [Related]

  • 18. The relative expression of Mig6 and EGFR is associated with resistance to EGFR kinase inhibitors.
    Chang X, Izumchenko E, Solis LM, Kim MS, Chatterjee A, Ling S, Monitto CL, Harari PM, Hidalgo M, Goodman SN, Wistuba II, Bedi A, Sidransky D.
    PLoS One; 2013 Aug 01; 8(7):e68966. PubMed ID: 23935914
    [Abstract] [Full Text] [Related]

  • 19. MP470, a novel receptor tyrosine kinase inhibitor, in combination with Erlotinib inhibits the HER family/PI3K/Akt pathway and tumor growth in prostate cancer.
    Qi W, Cooke LS, Stejskal A, Riley C, Croce KD, Saldanha JW, Bearss D, Mahadevan D.
    BMC Cancer; 2009 May 11; 9():142. PubMed ID: 19432987
    [Abstract] [Full Text] [Related]

  • 20. Resistance to EGFR-TKI can be mediated through multiple signaling pathways converging upon cap-dependent translation in EGFR-wild type NSCLC.
    Patel MR, Jay-Dixon J, Sadiq AA, Jacobson BA, Kratzke RA.
    J Thorac Oncol; 2013 Sep 11; 8(9):1142-7. PubMed ID: 23883783
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.